VIDEO: ‘Provocative’ observational study assesses DMARD use in RA-ILD

ByJeffrey A. Sparks, MD, MMSc

ByMarley V. Ghizzone

Fact checked byKatrina Altersitz

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, highlights an observational study investigating the impact of disease-modifying antirheumatic drugs on rheumatoid arthritis-associated interstitial lung disease.

“Overall, this was a pretty provocative study,” Sparks, an associate professor of medicine at Harvard Medical School and an associate program director of the Rheumatology Fellowship, director of Immuno-Oncology and Autoimmunity and director of the Joint Biology Consortium Human Biosamples Core at Brigham and Women’s Hospital, said of the study presented at ACR Convergence 2024. “It’s the most expansive, well designed observational study looking at DMARDs in RA-ILD outcomes.”

Reference:

Frideres H, et al. Abstract #1713. Presented at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Sparks reports receiving research support from Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson and Sonoma Biotherapeutics; and serving as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius Kabi, Gilead Sciences, Inova Diagnostics, Johnson & Johnson, Merck, MustangBio, Novartis, Optum, Pfizer, ReCor, Sana, Sobi and UCB.

Discoveries in Rheumatoid Arthritis

Read more

VIDEO: ‘Provocative’ observational study assesses DMARD use in RA-ILD

Reference:

Related Content